The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 555-565

  Gana Weisz, Mali ^a   Halaschek Wiener, Julius ^b   Jansen, Burkhard ^b   Elad, Galit ^a   Haklai, Ronit ^a   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FARNESYLTHIOSALICYLIC ACID; GEMCITABINE; PROTEIN INHIBITOR; RAS PROTEIN;

APOPTOSIS; ARTICLE; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL TRANSFORMATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAVEOLIN 1; CAVEOLINS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FARNESOL; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PHALLOIDINE; RAS PROTEINS; RATS; SALICYLIC ACIDS; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0036184738     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Ras oncogenes in human cancer: A review
2. Cell transformation by ras and regulation of its protein product
3. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells
4. Proteins regulating Ras and its relatives
5. Ras signalling and apoptosis
6. Function and regulation of ras
7. Understanding Ras. 'it ain't over 'til it's over'
8. The Ras branch of small GTPases: Ras family members don't fall far from the tree
9. All ras proteins are polyisoprenylated but only some are palmitoylated
10. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
11. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
12. Novel determinants of H-Ras plasma membrane localization and transformation
13. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
14. p21ras is modified by a farnesyl isoprenoid
15. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
16. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
17. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
18. K-, and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
19. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth
20. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid
21. Membrane interactions of a constitutively active GFP-K-Ras 4B and their role in signaling: Evidence from lateral mobility studies
22. Dislodgment and accelerated degradation of Ras
23. Novel ras antagonist blocks human melanoma growth
24. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist
25. Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid
26. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice
27. Cancer multidrug resistance
28. Multidrug resistance: A solvable problem?
29. Multidrug resistance in human tumors-molecular diagnosis and clinical significance
30. Cancer treatment: The last 25 years
31. Drug resistance in colon cancer
32. Overview of chemotherapy for pancreatic cancer
33. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation
34. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells
35. How Map kinases are regulated
36. Microtubule-associated protein 2 kinases, ERK1 and ERK2, undergo autophosphorylation on both tyrosine and threonine residues: Implications for their mechanism of activation
37. The caveolae membrane system
38. Functional, rafts in cell membranes
39. Crowded little caves: Structure and function of caveolae
40. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains
41. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and cofractionates with dystrophin and dystrophin-associated glycoproteins
42. Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane
43. Reduction of caveolin and caveolae in oncogenically transformed cells
44. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer
45. The role of gemcitabine in the treatment of other tumours
46. Gemcitabine: Progress in the treatment of pancreatic cancer
47. Esophageal cancer
48. Establishment of drug resistance in human gastric and colon carcinoma xenograft lines
49. Interaction of prenylcysteine methyl esters with the multidrug resistance transporter
50. Stringent structural requirements for anti-Ras activity of S-prenyl analogues
51. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains
52. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer
53. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth
54. Mechanisms and consequences of activation of protein kinase B/Akt
55. Classification of human colorectal adenocarcinoma cell lines
56. Signal transduction from multiple Ras effectors
57. Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells
58. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
59. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF
60. Disruption of TGF-β growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization
61. Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells